Trial Profile
A Phase II, Multi-center, Open-label, Single-Arm Study to Evaluate the Efficacy and Safety of Oral LDK378 Treatment for Patients With ALK-Positive Non-Small Cell Lung Cancer Previously Treated With Alectinib
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ceritinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ASCEND-9
- Sponsors Novartis Pharmaceuticals
- 01 Sep 2018 Results published in the Cancer Science
- 27 Jul 2018 Status changed from active, no longer recruiting to completed.
- 18 Oct 2017 Results including ORR, DCR, TTR, DOR, PFS, safety and exploratory biomarker data will be presented at the 2017 WCLC.